Stoke Therapeutics (NASDAQ:STOK) Trading Down 6.4%

Stoke Therapeutics, Inc. (NASDAQ:STOK)’s stock price fell 6.4% on Friday . The company traded as low as $11.21 and last traded at $11.24. 166,214 shares changed hands during trading, a decline of 82% from the average session volume of 940,320 shares. The stock had previously closed at $12.01.

Analysts Set New Price Targets

A number of equities research analysts recently commented on STOK shares. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Monday. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday. Canaccord Genuity Group lowered their price objective on shares of Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday. Wedbush increased their price objective on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. Finally, TD Cowen raised shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 26th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Stoke Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $20.57.

Stoke Therapeutics Trading Down 4.4 %

The business’s 50 day moving average is $10.39 and its two-hundred day moving average is $6.75.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Monday, March 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.02. The firm had revenue of $2.80 million for the quarter, compared to analyst estimates of $3.70 million. On average, research analysts predict that Stoke Therapeutics, Inc. will post -2.28 EPS for the current year.

Insider Buying and Selling

In related news, General Counsel Jonathan Allan sold 5,126 shares of Stoke Therapeutics stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $13.20, for a total transaction of $67,663.20. Following the transaction, the general counsel now directly owns 2,598 shares of the company’s stock, valued at $34,293.60. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, General Counsel Jonathan Allan sold 5,126 shares of Stoke Therapeutics stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $13.20, for a total value of $67,663.20. Following the transaction, the general counsel now owns 2,598 shares of the company’s stock, valued at approximately $34,293.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Skorpios Trust sold 3,600,000 shares of Stoke Therapeutics stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total value of $41,760,000.00. Following the completion of the transaction, the insider now directly owns 10,843,681 shares in the company, valued at approximately $125,786,699.60. The disclosure for this sale can be found here. Insiders have sold a total of 3,622,741 shares of company stock valued at $41,935,115 over the last three months. Company insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP lifted its position in Stoke Therapeutics by 514.7% in the 3rd quarter. GSA Capital Partners LLP now owns 348,069 shares of the company’s stock valued at $1,371,000 after acquiring an additional 291,443 shares in the last quarter. Trexquant Investment LP lifted its position in Stoke Therapeutics by 166.9% in the 3rd quarter. Trexquant Investment LP now owns 127,581 shares of the company’s stock valued at $503,000 after acquiring an additional 79,785 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Stoke Therapeutics by 9.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 146,076 shares of the company’s stock valued at $576,000 after acquiring an additional 12,478 shares in the last quarter. Corton Capital Inc. bought a new stake in Stoke Therapeutics in the 3rd quarter valued at $58,000. Finally, Public Employees Retirement System of Ohio bought a new stake in Stoke Therapeutics in the 3rd quarter valued at $64,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.